Barber Melissa N, Gaspari Tracey A, Kairuz Evette M, Dusting Gregory J, Woods Robyn L
Howard Florey Institute, University of Melbourne, Melbourne, Vic. 3010, Australia.
J Vasc Res. 2005 Mar-Apr;42(2):101-10. doi: 10.1159/000083429. Epub 2005 Jan 19.
Atrial and C-type natriuretic peptides (ANP and CNP), acting through different receptors, have antiproliferative effects in vitro. Beneficial effects of CNP in vivo on early atherosclerosis have been described, but it is not known if ANP is antiproliferative in vivo. In the present study, the effects of chronic in vivo ANP were tested and compared with CNP on endothelial dysfunction and intimal thickening caused by peri-arterial collars.
Non-occlusive collars were placed bilaterally around the common carotid arteries of rabbits. One collar was filled with saline vehicle. The contralateral collar was filled with ANP or CNP (1 or 10 microM, n = 5-7) with slow replacement of peptide via mini-pump (1 or 10 fmol/h).
After 7 days, endothelium-dependent vasorelaxation in saline-collared arteries was 33 +/- 3% of maximum [averaged over 0.03-1 muM acetylcholine (ACh)] compared to 64 +/- 2% in normal (uncollared) arteries (p < 0.05, n = 23). In vivo ANP restored the ACh relaxation to normal (e.g., 57 +/- 6%, 1 microM ANP), similar to effects seen with CNP in vivo. Endothelium-independent vasorelaxation of collared-vessels was not altered by either peptide. Intimal hyperplasia induced by the collars was not prevented by peri-arterial natriuretic peptides. In additional rabbits (n = 6), CNP (100 pmol/h) given directly into the lumen of collared carotid arteries for 7 days reduced neointima formation by 16 +/- 5% (p < 0.05), whereas ANP given intraluminally (100 pmol/h; n = 6) did not.
The more potent actions of CNP on vascular smooth muscle cell migration and proliferation (established in vitro) may explain differences between the peptides on intimal hyperplasia in vivo. The major hallmark of atherosclerosis and restenosis, endothelial dysfunction, was prevented by chronic, peri-arterial administration of ANP or CNP.
心房钠尿肽和C型钠尿肽(ANP和CNP)通过不同受体发挥作用,在体外具有抗增殖作用。已报道CNP在体内对早期动脉粥样硬化有有益作用,但尚不清楚ANP在体内是否具有抗增殖作用。在本研究中,测试了慢性体内给予ANP的效果,并与CNP对动脉周围套环引起的内皮功能障碍和内膜增厚的影响进行了比较。
在兔双侧颈总动脉周围放置非闭塞性套环。一个套环填充生理盐水。对侧套环填充ANP或CNP(1或10微摩尔,n = 5 - 7),通过微型泵缓慢更换肽(1或10飞摩尔/小时)。
7天后,生理盐水套环动脉的内皮依赖性血管舒张为最大舒张的33±3%[0.03 - 1微摩尔乙酰胆碱(ACh)平均水平],而正常(未套环)动脉为64±2%(p < 0.05,n = 23)。体内给予ANP可将ACh舒张恢复至正常水平(例如,1微摩尔ANP时为57±6%),与体内给予CNP的效果相似。肽类对套环血管的非内皮依赖性血管舒张无影响。动脉周围钠尿肽不能预防套环引起的内膜增生。在另外的兔(n = 6)中,将CNP(100皮摩尔/小时)直接注入套环颈总动脉腔内7天,可使新生内膜形成减少16±5%(p < 0.05),而腔内给予ANP(100皮摩尔/小时;n = 6)则无此作用。
CNP对血管平滑肌细胞迁移和增殖的更强作用(已在体外证实)可能解释了肽类在体内对内膜增生影响的差异。动脉粥样硬化和再狭窄的主要标志,即内皮功能障碍,可通过慢性动脉周围给予ANP或CNP来预防。